Under pressure to rebuild as sales of its blockbuster Lantus slide, Sanofi desperately needed the launch of its Dengue vaccine to run smoothly. But it hasn’t. Analysts had expected blockbuster ...

Named Dengvaxia, it is the product of 20 years research by Sanofi Pasteur, the vaccines division of Paris-based Sanofi, and could help prevent millions of people from being infected with the ...

Dengvaxia manufacturer Sanofi Pasteur Inc. even issued a warning over health risks for those who had not contracted dengue ...

PAO said a Sanofi declaration and admission for authorization of the four fatal identified risks associated with Dengvaxia — neurotropism, viscerotropism, severe dengue and anaphylaxis ...